Skip to main content
. 2022 Feb 14;22:114. doi: 10.1186/s12888-022-03758-w

Fig. 3.

Fig. 3

Return to Baseline Weight After Treatment Interruption With Oral SGAs Associated With Moderate to High Risk of Weight Gain. BD-I, bipolar I disorder; CSWG, clinically significant weight gain; SGA, second-generation antipsychotic; SZ, schizophrenia